Tim Oldham
Chief Executive Officer Ad Alta
Tim became CEO/MD of AdAlta, a company now focussed on globalising Asian cellular immunotherapies under its “East to West” strategy, in 2019. He is also Chair of Skin2Neuron Pty Ltd, a company developing regenerative cell therapies for neurodegenerative diseases. He has more than 20 years of life sciences business development, product development and commercialisation experience in Europe, Asia and Australia. Previous roles include CEO and Managing Director of Cell Therapies Pty Ltd, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd. Prior to this, Tim was an engagement manager with McKinsey & Company.
Seminars
Tuesday 9th February 2027
Harnessing the Best of East & West to Accelerate Global Cell Therapy Development
11:30 am
- Identifying the operational, strategic, and partnership frameworks required to leverage China’s pace and cost advantages while meeting the expectations of global markets
- Designing manufacturing strategies that support scalable development, regulatory compliance, and seamless commercialisation across multiple geographies
- EW-001 armoured CAR-T case study highlighting regulatory considerations, operational efficiencies, and approaches to accelerate global development timelines
Tuesday 9th February 2027
Panel Discussion: Why China, Why Now? Evaluating the Opportunities, Risks & Realities of Operating in China
12:00 pm
- Assessing the advantages and trade-offs of Chinese development and manufacturing, to determine the optimal balance between speed, cost, quality, effort, and long-term clinical strategy
- Navigating IIT pathways and regulatory requirements to support future clinical and regulatory success in Asia, the US and Europe
- Examining the investment and commercial implications of conducting trials and manufacturing in China, to accelerate asset interest and global market opportunities
